5) molecular diagnosis of glioma was introduced into WHO classification in 2016, therefore, detailed molecular pathological data are often not available in the historical control group, such as MGMT promoter methylation, IDH mutation, or CDKN2A/B deletion status (31).In view of the disadvantages of the above-mentioned single-arm trials, the currently recommended trial design scheme for clinical trials is a randomized trial (97). This evidence concerns the gene MGMT and central nervous system cancer.